BioSpace News Archive

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing the acquisition of the assets of Geetha, LLC, an adaptive, conversational AI company.

H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of four posters providing updated investigational data on its H3B-6545 clinical program for breast cancer and its H3B-6527 clinical program for hepatocellular carcinoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4–8,

The Acessa® procedure is a minimally invasive treatment alternative to hysterectomy for women who have symptomatic fibroids

Kaku et al. Long-term efficacy and safety in Phase 3 study with Imeglimin as mono- and add-on therapy in Japanese T2DM patients: results from TIMES 2 trial Hata et al. Post hoc analysis of Phase 2 and 3 studies of Imeglimin – similar efficacy and consistent safety in patients with different backgrounds, including elderly patients and those with renal impairment

Lumenix is pleased to announce that the Federal Government of Canada has purchased its Artificially Intelligent Monitoring System for hand hygiene to deploy at The Ottawa Hospital, one of the largest teaching and research hospitals in Canada.

Funds will support preclinical verification studies of its Total Artificial Heart in preparation for first in human early feasibility studies.

Life Sciences Ontario has announced the launch of the document, Leading the Way Toward Recovery, Resilience and Prosperity: Roadmap for an Integrated Life Sciences Ecosystem, a follow up to the 2017 Blueprint for a Coordinated Life Sciences Strategy.

Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of its cloud-based data and analytics platform, Lens.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 Pivotal clinical trial of COVI-MSC™, an injectable infusion of mesenchymal stem cells, for the treatment of hospitalized COVID-19 patients suffering from ARDS.

Ceapro Inc.(TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended March 31, 2021.